GlobeNewswire·Nov 5, 2026, 10:42 PM ET

Orchestra BioMed Announces Pricing of Public Offering

Orchestra BioMed Holdings, Inc. priced an underwritten public offering of 15,000,000 shares of common stock at $5.00 per share.
The company granted underwriters a 30-day option to purchase up to an additional 2,250,000 shares at the public offering price.
The offering is expected to close on November 9, 2026, subject to customary closing conditions.
Gross proceeds from the offering are expected to be $75.0 million, assuming no exercise of the underwriters' option.
Net proceeds will fund the AVIM Therapy program, the BACKBEAT global pivotal trial for uncontrolled hypertension, the Virtue SAB program, the Virtue Trial for coronary in-stent restenosis, other research, & general corporate purposes.
Piper Sandler & TD Cowen are acting as joint bookrunning managers, BTIG is a bookrunner, & H.C. Wainwright & Co. is the lead manager.
The securities are offered pursuant to a shelf registration statement on Form S-3 filed with the SEC on May 15, 2024.
AVIM Therapy is a bioelectronic treatment for hypertension in pacemaker-indicated patients that has completed enrollment in the BACKBEAT Trial & holds two FDA Breakthrough Device Designations.
Virtue SAB is a drug delivery balloon system currently enrolling patients in the Virtue Trial & holds FDA Breakthrough Device Designations for coronary in-stent restenosis, coronary small vessel disease, & below-the-knee peripheral artery disease.